Search results for " Progesterone"

showing 10 items of 83 documents

Membranous dysmenorrhoea in a woman undergoing hormone replacement preparation for embryo transfer - a peculiar case

2023

Membranous dysmenorrhoea is an uncommon condition characterized by the spontaneous flaking of endometrium into a single piece that maintains the shape of the uterus. The common symptom of membranous dysmenorrhoea is a colicky pain caused by uterine contractions. Because only a limited number of cases have been published in the literature, the case report we present is peculiar. This report describes a case of membranous dysmenorrhoea that occurred after an artificial frozen thawed embryo transfer cycle using vaginal progesterone. The patient, during hormone replacement treatment, reported an intense abdominal colicky pain resulting in the loss of membranous endometrial tissue. A histopathol…

IVFEndocrinology Diabetes and Metabolismembryo transfer; IVF; luteal support; membranous dysmenorrhoea; progesteroneObstetrics and GynecologyProgesterone.Embryo transferprogesteroneLuteal supportMembranous dysmenorrhoeaSettore MED/40 - Ginecologia E Ostetricia
researchProduct

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

2019

Data from 423 human epidermal growth factor receptor 2-negative (HER2−), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) and clinical benefit was 52.7% (95% CI, 48–57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At…

Male0301 basic medicineOncologyPyridinesReceptor ErbB-2PhysiologyClinical BiochemistryPiperazineschemistry.chemical_compound0302 clinical medicineExemestaneAntineoplastic Combined Chemotherapy Protocolsadvanced breast cancer; hormonal therapy; endocrine resistance; palbociclib; real-world settingBreastAged 80 and overadvanced breast cancerhormonal therapyadvanced breast cancer hormonal therapy; endocrine resistance; palbociclib; real-world settingMiddle AgedTreatment OutcomeReceptors Estrogen030220 oncology & carcinogenesisToxicityFemaleReceptors Progesteronemedicine.drugAdultadvanced breast cancer hormonal therapy; endocrine resistance; palbociclib; real-world setting; Physiology; Clinical Biochemistry; Cell Biologymedicine.medical_specialtypalbociclibBreast NeoplasmsPalbociclibNeutropeniaadvanced breast cancer hormonal therapyDisease-Free Survivalendocrine resistance03 medical and health sciencesInternal medicinereal-world settingmedicineHumansAgedEverolimusSettore MED/06 - ONCOLOGIA MEDICAbusiness.industryCancerCell Biologymedicine.diseaseConfidence interval030104 developmental biologychemistryMED/06 - ONCOLOGIA MEDICAbusinessHormone
researchProduct

Gut microbiota steroid sexual dimorphism and its impact on gonadal steroids: influences of obesity and menopausal status

2020

[Background]: Gonadal steroid hormones have been suggested as the underlying mechanism responsible for the sexual dimorphism observed in metabolic diseases. Animal studies have also evidenced a causal role of the gut microbiome and metabolic health. However, the role of sexual dimorphism in the gut microbiota and the potential role of the microbiome in influencing sex steroid hormones and shaping sexually dimorphic susceptibility to disease have been largely overlooked. Although there is some evidence of sex-specific differences in the gut microbiota diversity, composition, and functionality, the results are inconsistent. Importantly, most of these studies have not taken into account the go…

Male:Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cross-Sectional Studies [Medical Subject Headings]PhysiologyGut flora:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Mice:Chemicals and Drugs::Hormones Hormone Substitutes and Hormone Antagonists::Hormones::Gonadal Hormones [Medical Subject Headings]0302 clinical medicineOverweight persons:Organisms::Eukaryota::Animals [Medical Subject Headings]TestosteroneProgesteronaGonadal Steroid HormonesTestosteronaTestosteroneProgesterone:Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings]Sex Characteristics0303 health sciencesMicrobiotaIntestins -- MalaltiesMiddle AgedSex ; Gender ; Gonadal steroids ; Testosterone ; Progesterone ; Microbiome ; Sexual dimorphism.Persones obeses3. Good healthMenopause:Phenomena and Processes::Microbiological Phenomena::Microbiota [Medical Subject Headings]Intestins -- MicrobiologiaCaracteres sexualeslcsh:QR100-130Female:Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Climacteric::Menopause [Medical Subject Headings]SexAnimal studiesIntestines -- DiseasesMenopauseMenopausaAdultMicrobiology (medical):Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Sex Characteristics [Medical Subject Headings]:Check Tags::Male [Medical Subject Headings]SexoSteroid biosynthesisBiologyIntestines -- Microbiologydigestive systemMicrobiologylcsh:Microbial ecology:Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings]03 medical and health sciencesSexual dimorphismmedicineAnimalsHumansObesityMicrobiome:Persons::Persons::Age Groups::Adult [Medical Subject Headings]Aged030304 developmental biology:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice [Medical Subject Headings]ResearchGender:Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]medicine.diseasebiology.organism_classificationObesityGastrointestinal Microbiome:Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings]Gonadal steroidsSexual dimorphismCross-Sectional Studies:Check Tags::Female [Medical Subject Headings]Case-Control StudiesIdentidad de géneroMicrobiome030217 neurology & neurosurgeryMicrobiome
researchProduct

Expression pattern of estroprogestinic receptors in sinonasal inverted papilloma

2017

// Agostino Serra 1 , Rosario Caltabiano 2 , Giacomo Spinato 3 , Salvatore Gallina 4 , Salvatore Caruso 5 , Venerando Rapisarda 6 , Paola Di Mauro 1 , Veronica Castro 1 , Angelo Conti 1 , Luisa Licciardello 1 , Luigi Maiolino 1 , Salvatore Lanzafame 2 , Salvatore Cocuzza 1 1 Department of Medical and Surgical Sciences and Advanced Technologies “G. Ingrassia”, ENT Section, University of Catania, Catania, Italy 2 Department of Medical and Surgical Sciences and Advanced Technologies “G. Ingrassia”, Section of Anatomic Pathology, University of Catania, Catania, Italy 3 ENT Department, Rovigo Provincial Hospital, Rovigo, Italy 4 Department of Experimental Biomedicine and Clinical Neurosciences, …

Malemedicine.medical_specialtyReceptor expressionNose NeoplasmsInverted papillomaMalignancyBenign tumor03 medical and health sciencesinverted papilloma0302 clinical medicineHuman papilloma viruhuman papilloma virusmedicineBiomarkers TumorHormonal receptor expression; Human papilloma virus; Immunohistochemistry; Inverted papilloma; Paranasal sinuses; OncologyHumanshormonal receptor expression030223 otorhinolaryngologyAgedRetrospective StudiesPapilloma Invertedbusiness.industryGeneral surgeryAnatomical pathologyMiddle Agedmedicine.diseaseSurgeryParanasal sinusesmedicine.anatomical_structureParanasal sinuseOtorhinolaryngologyOncologyReceptors EstrogenParanasal sinuses inverted papilloma human papilloma virus hormonal receptor expression immunohistochemistry030220 oncology & carcinogenesisimmunohistochemistryEtiologyFemaleNeoplasm Recurrence LocalbusinessReceptors ProgesteroneParanasal sinusesResearch Paper
researchProduct

Steroid hormone receptors in human melanoma.

1981

Human melanomas were investigated for the presence of high-affinity estrogen-, gestagen-, and glucocorticoid-binding proteins. A statistically significant difference was found for mean estrogen receptor (ER) concentrations in melanomas of male versus female origin: female origin 37.6 (0-107) fmol/mg protein, male origin 3.9 (0-8.3) fmol/mg protein. No significant difference between sexes was found for gestragen receptors: 41.5 (0-194) fmol/mg protein for melanomas of female origin versus 99 (0-362) fmol/mg protein for male. Sucrose density gradient analyses revealed specific binding for both receptor types in the 4-5 S region as well as in the 8 S region. The binding affinities were in the …

Malemedicine.medical_specialtyReceptors SteroidSkin Neoplasmsmedicine.drug_classmedicine.medical_treatmentEstrogen receptorDermatologyBiologyCytosolReceptors GlucocorticoidSex FactorsInternal medicinemedicineCentrifugation Density GradientHumansReceptorMelanomaEstrogen receptor betaSignificant differenceGeneral MedicineSteroid hormoneEndocrinologyReceptors EstrogenEstrogenHuman melanomaFemaleReceptors ProgesteroneArchives of dermatological research
researchProduct

Association of low-penetrance alleles with male breast cancer risk and clinicopathological characteristics: results from a multicenter study in Italy

2013

It is well-known that male breast cancer (MBC) susceptibility is mainly due to high-penetrance BRCA1/2 mutations. Here, we investigated whether common low-penetrance breast cancer (BC) susceptibility alleles may influence MBC risk in Italian population and whether variant alleles may be associated with specific clinicopathological features of MBCs. In the frame of the Italian Multicenter Study on MBC, we genotyped 413 MBCs and 745 age-matched male controls at 9 SNPs annotating known BC susceptibility loci. By multivariate logistic regression models, we found a significant increased MBC risk for 3 SNPs, in particular, with codominant models, for rs2046210/ESR1 (OR = 1.71; 95 % CI: 1.43–2.05;…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisSettore MED/06 - Oncologia MedicaClinicopathological characteristicBRCA1/2; Clinicopathological characteristics; ER/PR status; Low-penetrance breast cancer alleles; Male breast cancer; SNPsSingle-nucleotide polymorphismPolymorphism Single NucleotideER/PR statuBreast Neoplasms MaleBreast cancerBRCA1/2Internal medicineGenotypemedicineHumansGenetic Predisposition to DiseaseAlleleReceptor Fibroblast Growth Factor Type 2Low-penetrance breast cancer alleleAllelesAgedAged 80 and overbusiness.industryEstrogen Receptor alphaHigh Mobility Group Proteinsclinicopathological characteristicsMiddle Agedmedicine.diseasePenetranceMale breast cancerer/pr statusOncologyTOX3ItalyReceptors EstrogenMale breast cancerCase-Control StudiesMultivariate AnalysisTrans-Activatorslow-penetrance breast cancer allelesbusinessApoptosis Regulatory ProteinsReceptors Progesteroneclinicopathological characteristics; er/pr status; male breast cancer; brca1/2; snps; low-penetrance breast cancer allelesSNPs
researchProduct

An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer.

2012

Abstract Purpose Whether or not to biopsy the metastasis in recurrent breast cancer has become mired in controversy. Several studies have shown an important discordance of the immunohistochemical (IHC) determinations for ER, PR and HER2 between primary (PT) and recurrent tumors (RT). Yet it remains unknown within this what impact technical issues have. The aim of our study was to assess whether technical variability might have an impact on the concordance between PT and RT. Methods IHC determinations in paired biopsies from PT and RT were compared under routine vs study conditions. In the former, pathological analysis reproduced the conditions used in the routine of a University Pathology D…

OncologyAdultmedicine.medical_specialtyReceptor ErbB-2ConcordanceBone NeoplasmsBreast NeoplasmsMetastasisBreast cancerInternal medicineBiopsymedicineHumansPathologicalAgedRetrospective StudiesGynecologyAged 80 and overmedicine.diagnostic_testbusiness.industryConfoundingGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerImmunohistochemistryReceptors EstrogenImmunohistochemistrySurgeryFemalebusinessReceptors ProgesteroneBreast (Edinburgh, Scotland)
researchProduct

Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research

2010

Breast cancer is a heterogeneous disease with different morphologies, molecular profiles, clinical behaviour and response to therapy. The triple negative is a particular type of breast cancer defined by absence of oestrogen and progesterone receptor expression as well as absence of ERBB2 amplification. It is characterized by its biological aggressiveness, worse prognosis and lack of a therapeutic target in contrast with hormonal receptor positive and ERBB2+ breast cancers. Given these characteristics, triple-negative breast cancer is a challenge in today's clinical practice. A new breast cancer classification emerged recently in the scientific scene based in gene expression profiles. The ne…

OncologyCA15-3medicine.medical_specialtyMicroarrayReceptor ErbB-2business.industryCancerBreast NeoplasmsGeneral MedicineDiseasemedicine.diseaseBreast cancerReceptors EstrogenOncologyInternal medicinemedicineHumansFemaleRadiology Nuclear Medicine and imagingReceptors Progesteroneskin and connective tissue diseasesBreast cancer classificationbusinessTriple-negative breast cancerEGFR inhibitorsCancer Treatment Reviews
researchProduct

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HE…

2020

We analyzed data from 738 HER2‐positive metastatic breast cancer (mbc) patients treated with pertuzumab‐based regimens and/or T‐DM1 at 45 Italian centers. Outcomes were explored in relation to tumor subtype assessed by immunohistochemistry (IHC). The median progression‐free survival at first‐line (mPFS1) was 12 months. Pertuzumab as first‐line conferred longer mPFS1 compared to other first‐line treatments (16 vs. 9 months, p = 0.0001), regardless of IHC subtype. Median PFS in second‐line (mPFS2) was 7 months, with no difference by IHC subtype, but it was more favorable with T‐DM1 compared to other agents (7 vs. 6 months, p = 0.03). There was no PFS2 gain in patients with tumors expressing b…

OncologyCancer ResearchMultivariate analysisSettore MED/06 - Oncologia MedicaReceptor ErbB-2T-DM1Estrogen receptor0302 clinical medicineErbB-2TrastuzumabReceptorsAntineoplastic Combined Chemotherapy Protocols80 and overMolecular Targeted TherapyNeoplasm MetastasisCancer Therapy and PreventionProgesteroneAged 80 and overadvanced breast cancerTumorreal worldMiddle AgedPrognosisMetastatic breast cancerImmunohistochemistryGene Expression Regulation NeoplastictrastuzumabOncologyReceptors Estrogen030220 oncology & carcinogenesisImmunohistochemistryFemaleadvanced breast cancer; HER2 positive; pertuzumab; real world; T-DM1; trastuzumab; Adult; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers Tumor; Breast Neoplasms; Female; Humans; Immunohistochemistry; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Receptor ErbB-2; Receptors Estrogen; Receptors Progesterone; Gene Expression Regulation NeoplasticPertuzumabReceptors ProgesteroneHER2 positive; T-DM1; advanced breast cancer; pertuzumab; real world; trastuzumabmedicine.drugReceptorAdultHER2 positivemedicine.medical_specialtyT‐DM1advanced breast cancer; HER2 positive; pertuzumab; real world; T-DM1; trastuzumab; chemotherapyBreast Neoplasms03 medical and health sciencesBreast cancerSettore MED/04 - PATOLOGIA GENERALEpertuzumabInternal medicinemedicineBiomarkers TumorHumansAgedNeoplasm StagingNeoplasticbusiness.industrymedicine.diseaseEstrogenSettore CHIM/08 - Chimica FarmaceuticaGene Expression RegulationMED/06 - ONCOLOGIA MEDICAbusinessBiomarkersHormone
researchProduct

Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience

2011

Abstract Aims Triple-negative breast cancers (TNBCs) lack expression of oestrogen, progesterone, and Human Epidermal Growth Factor 2 receptors. The NEMESI study described current Italian treatment practices in patients with operable, early-stage breast cancer (EBC). Patients and methods Retrospective, observational study involving 63 Italian oncology centres. Eligible patients were aged ⩾18 years with EBC (stage I–II) who had undergone surgery, received ⩾1 cycle of adjuvant chemotherapy and/or adjuvant hormonal therapy and attended an oncology centre between 1 January 2008 and 30 June 2008. This subanalysis focused on patients with TNBC. Variables evaluated included: demographic data/clinic…

OncologyCancer ResearchSettore MED/06 - Oncologia MedicaReceptor ErbB-2receptormedicine.medical_treatmentreceptorsGuidelineClinical practicechemotherapyAntineoplastic Combined Chemotherapy ProtocolsestrogenMedicineStage (cooking)Triple-negative breast cancerAdjuvant therapy Clinical practice Guidelines Italy National register Triple-negative breast cancer --------------------------------------------------------------------------------Middle AgedCombined Modality TherapyReceptors EstrogenItalyOncologyChemotherapy AdjuvantHormonal therapyFemaleReceptors Progesteronemedicine.medical_specialtyNational registerBreast NeoplasmsprogesteroneGuidelinesAdjuvant therapyBreast canceradjuvantTriple-negative breast canceradjuvant therapy; clinical practice; guidelines; italy; national register; triple-negative breast cancer; aged; antineoplastic combined chemotherapy protocols; breast neoplasms; chemotherapy adjuvant; combined modality therapy; female; humans; italy; middle aged; radiotherapy adjuvant; receptor erbb-2; receptors estrogen; receptors progesterone; retrospective studiesInternal medicineAdjuvant therapyHumansradiotherapyAgedRetrospective StudiesChemotherapybusiness.industryTriple-negative breast cancer --------------------------------------------------------------------------------medicine.diseaseRadiation therapyAged Antineoplastic Combined Chemotherapy Protocols; therapeutic use Breast NeoplasmsRadiotherapy AdjuvantObservational studybusinesserbb-2
researchProduct